Author

Md Shamsuzzaman

Observed names: - Md Shamsuzzaman, M Shamsuzzaman, MD Shamsuzzaman, S. M. SHAMSUZZAMAN, M. FURUYA, M. KORE

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Mid Cheshire Hospitals NHS Foundation Trust, Leighton Hospital, Bristol-Myers Squibb (United States), Shaheed Suhrawardy Medical College, Dhaka National Medical College, Dhaka Medical College and Hospital

OpenAlex ID: A5000717195

Use of urine samples from healthy humans, nephritis patients or other animals as an alternative to foetal calf serum in the culture of Leishmania (L.) donovani in vitro

1999 · S. M. SHAMSUZZAMAN, M. FURUYA, M. KORE · Annals of Tropical Medicine and Parasitology · 20

Clinical Profile, Haematological Changes and Outcomes of Dengue Patients in Dengue Outbreak-2019 in Jashore, Bangladesh- An Observational Study

2021 · Mohammad Ali, Goutam Kumar Acherjya, et al. · Journal of Medicine · 6

P-069 Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa

2024 · Larry Anderson, Jesús San-Miguel, et al. · Clinical Lymphoma Myeloma & Leukemia · 2

Thyroid Function Status during Different Trimesters in Bangladeshi Women

2022 · Shyamal Chandra Banik, Mahmuda Begum, et al. · Medicine Today · 1

Sensitivity of Alvarado Score among the Suspected Appendicitis Patients at a Tertiary Level Teaching Hospital

2020 · - Md Shamsuzzaman, Md Alamgir Hossain Sikder, et al. · Medicine Today · 1

Groin Flap: A Good Converge for Hand Injury

1970 · Md Shamsuzzaman, SK Borhan Uddin, et al. · Journal of Medicine · 1

Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.

2024 · Sanhita Sengupta, Clara Amorosi, et al. · Journal of Clinical Oncology

P809: Baseline Characteristics Identifying Patients With Multiple Myeloma Treated With Idecabtagene Viceleucel (ide-cel; Bb2121) Who Are at Risk for Severe/refractory Inflammatory Adverse Events

2023 · Afshin Mashadi-Hossein, Julie Rytlewski, et al. · HemaSphere

Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs).

2023 · Afshin Mashadi-Hossein, Julie Rytlewski, et al. · Journal of Clinical Oncology

A Giant Mesentric Lipoblastoma in a Two-Year Girl: A Case Report

2021 · Paritosh Kumar Palit, Abhi Kumar Chakroborty, et al. · Journal of Shaheed Suhrawardy Medical College

Successful Separation of Conjoined Twins: Experience of a Tertiary Care Hospital

2018 · Shahnoor Islam, Sadruddin Al Masud, et al. · Bangladesh Journal of Child Health

Serum LDL Cholesterol/HDL Cholesterol Ratio Alternative to Albumin in Relation to Coronary Heart Disease

1970 · S Parveen, Md Shamsuzzaman, et al. · Journal of Medicine

Works count: 12

Citation count: 31

H-index: 2

I10-index: 1